surmount trials tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT‐1 study design. This is

As of early 2025, the FDA had received more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide figures that the agency now cites as active justification for enforcement

Gastrointestinal symptoms: alteration in bowel motility, such as mild diarrhea or constipation, and loss of bladder or bowel control

, 50 150 L- ,

Wraparound support New therapies for weight loss mean more choice for patients, eventually resulting in lower prices and more personalised approaches

BAC declines at approximately 0.015% per hour after peak absorption, meaning a BAC of 0.08% requires approximately 5.3 hours to reach 0.00% through metabolism alone

Weight Loss works by mimicking hormones that regulate appetite and blood sugar